Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue
Product sales	$ 1,496,759	$ 1,211,900	$ 2,997,481	$ 3,276,930
Cost of product sales	678,111	666,580	1,296,210	1,828,221
Gross profit	818,648	545,320	1,701,271	1,448,709
Operating expenses
Research and development	301,334	192,778	623,499	360,065
Sales and marketing	642,490	270,616	1,142,745	512,016
General and administrative	1,030,701	969,799	2,251,406	1,833,542
Total operating expenses	1,974,525	1,433,193	4,017,650	2,705,623
Operating loss	(1,155,877)	(887,873)	(2,316,379)	(1,256,914)
Other income (expenses)
Interest income	5,482	4,517	13,719	4,517
Interest expense	0	0	0	(177,308)
Amortization of deferred financing costs	0	0	0	(13,022)
Total other income (expenses)	5,482	4,517	13,719	(185,813)
Net Loss	(1,150,395)	(883,356)	(2,302,660)	(1,442,727)
Net loss attributable to non-controlling interest	156,016	0	276,799	0
Net Loss attributable to BioLife Solutions, Inc.	$ (994,379)	$ (883,356)	$ (2,025,861)	$ (1,442,727)
Basic and diluted net loss per common share attributable to BioLife Solutions, Inc.	$ (0.08)	$ (0.07)	$ (0.17)	$ (0.16)
Basic and diluted weighted average common shares used to calculate net loss per common share	12,144,776	12,010,361	12,122,667	8,807,376